Tags : Voyager


AbbVie Terminates Tau and ASN Agreement with Voyager Signed in

Shots: Voyager retains full rights to the vectorization technology and novel vectorized Abs emerges from the collaboration and has the right to pursue vectorized Ab programs targeting tau and alpha-synuclein alone or in collaboration with another partner As per collaboration agreements, Voyager has received an upfront payment to perform research and preclinical development of vectorized […]Read More


Voyager to Present Preclinical Data of VY-HTT01 & VY-SOD102 at

Shots: Voyager’s program for Huntington’s Disease and Amyotrophic Lateral Sclerosis assessing VY-HTT01 at five wks. post-dosing in adult non-human primates & VY-SOD102 one-time intraparenchymal infusion after laminectomy The program demonstrated reduction in HTT mRNA by 68% in the caudate, 67% in the putamen, 73% in the thalamus, and 32% in cortical neurons & reduction in […]Read More